Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed prostate cancer that is not the rare “small cell” type
- Your cancer is localized (treatable with surgery) and scans show no spread to distant organs or bones (enlarged lymph nodes may be allowed)
- Your prostate cancer is high or very high risk (for example, PSA over 20, or grade group 4–5, or stage T3a or higher)
- You must have adequate blood counts, liver tests, and kidney function from bloodwork
- You need to be well enough for treatment (performance status 0–1) and able to sign consent
- You must not currently be on prostate cancer hormone therapy and must avoid certain medicine interactions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a new enzalutamide implant (Enolen) placed in the prostate before surgery to see if it helps treat early prostate cancer. It is for men who are already planning to have their prostate removed.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.